Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.45 |
| ▸ | FNTA | P49354 | 2/20 | 0.33 |
| ▸ | FNTB | P49356 | 2/20 | 0.33 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8358468 | 0.93 | CYP11B1 (0.44) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL3582097 | 0.87 | CYP11B1 (0.45) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| Hydrochloric Acid SCHEMBL3568030 | 0.86 | CYP11B1 (0.45) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL13316220 | 0.84 | CYP11B1 (0.43) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL3581293 | 0.84 | CYP11B2 (0.57) | CYP11B1CYP11B2FNTAFNTBKCNH2 | |
| SCHEMBL8357162 | 0.84 | CYP11B1 (0.41) | CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL3572827 | 0.83 | CYP11B2 (0.56) | CYP11B1CYP11B2KCNH2 | |
| SCHEMBL3573721 | 0.82 | RORC (0.44) | CYP11B1CYP11B2FNTAFNTBKCNH2 | |
| SCHEMBL8358456 | 0.81 | CYP11B1 (0.54) | CYP11B1CYP11B2FNTAFNTB | |
| SCHEMBL3572522 | 0.81 | CYP11B1 (0.44) | CYP11B1CYP11B2FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004014914-A1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2004-02-19 | — | — | WO | disclosed |